Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 64, Issue 2, 2006, Pages 138-145

  Tafaghodi, Mohsen ^a,b   Jaafari, Mahmood Reza ^a   Sajadi Tabassi, Sayyed Abolghasem ^a,c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant; Antitoxin; CpG ODN; IgG; Nasal immunization; Neutral liposome; sIgA; Tetanus toxoid

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOSOME; TETANUS TOXOID;

ABSENCE OF SIDE EFFECTS; ADULT; ANIMAL EXPERIMENT; ANTIBODY TITER; APPLICATION SITE BURNING; APPLICATION SITE IRRITATION; ARTICLE; CONTROLLED STUDY; DEHYDRATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE IRRITATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; INFECTION PREVENTION; IRRITATIVE COUGHING; MUCOSAL IMMUNITY; NONHUMAN; NORMAL HUMAN; NOSE IRRITATION; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT; REHYDRATION; SIDE EFFECT; SNEEZING; TETANUS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; DRUG COMPOUNDING; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN A; LIPOSOMES; NASAL LAVAGE FLUID; OLIGODEOXYRIBONUCLEOTIDES; PARTICLE SIZE; RABBITS; TETANUS ANTITOXIN; TETANUS TOXOID;

EID: 33747875961     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.05.005     Document Type: Article

References (27)

1. Alpar H.O., Bowen J.C., and Brown M.R.W. Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid. Int. J. Pharm. 88 (1992) 335-344
2. Husband A.J. Novel vaccination strategies for the control of mucosal infection. Vaccine 11 (1993) 107-112
3. Bowersock T.L., Hogenesch H., Suckow M., Porter R.E., Jackson R., Park H., and Park K. Oral vaccination with alginate microsphere systems. J. Control. Release 39 (1996) 209-220
4. Rebelatto M.C., Guimond P., Bowersock T.L., and HogenEsch H. Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet. Immunol. Immunopathol. 83 (2001) 93-105
5. Gombotz W.R., and Wee S. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31 (1998) 267-285
6. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., and Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10 (1992) 75-88
7. Barenholz Y., and Crommelin D. Liposomes as pharmaceutical dosage forms. In: Swarbrick J., and Boylan E. (Eds). Encyclopedia of Pharmaceutical Technology (1994), Marcel Dekker, New York 1-39
8. Gregoriadis G., Gursel I., Gursel M., and McCormack B. Liposomes as immunological adjuvants and vaccine carriers. J. Control. Release 41 (1996) 49-56
9. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., Hayashi T., Takabayashi K., Barenholz Y., and Kedar A. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20 (2002) 3342-3354
10. Kim C.-K., and Jeong E.J. Development of dried liposome as effective immuno-adjuvant for hepatitis b surface antigen. Int. J. Pharm. 115 (1995) 193-199
11. Krieg A.M. Immune effects and mechanisms of action of CpG motifs. Vaccine 19 (2000) 618-622
12. Diwan M., Tafaghodi M., and Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control. Release 85 (2002) 247-262
13. Lin L., Serth A.J., and Peng S.L. CpG DNA redirects class-switching towards "Jh1-like" Ig isotype production via ThR9 and MyD88. Eur. J. Immunol. 34 (2004) 1483-1487
14. McCluskie M.J., and Davis H.L. CpG DNA as mucosal adjuvant. Vaccine 18 (1999) 231-237
15. Gregoriadis G., da Silva H., and Florence A.T. A procedure for the efficient entrapment of drugs in dehydration-rehydration liposomes (DRVs). Int. J. Pharm. 65 (1990) 235-242
16. Diwan M., Khar R.K., and Talwar G.P. Tetanus toxoid loaded 'preformed microspheres' of cross-linked dextran. Vaccine 19 (2001) 3853-3859
17. Dokmetjian J., Della Valle C., Lavigne V., de Lujan C.M., and Manghi M.A. A possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin. Vaccine 18 (2000) 2698-2703
18. Bjork E., and Edman P. Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int. J. Pharm. 62 (1990) 187-192
19. Bowersock T.L., Hogenesch H., Suckow M., Guimond P., Martin S., Borie D., Torregrosa S., Park H., and Park K. Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine 17 (1999) 1804-1811
20. Suckow M.A., Jarvinen L.Z., HogenEsch H., Park K., and Bowersock T.L. Immunization of rabbits against a bacterial pathogen with an alginate microparticle vaccine. J. Control. Release 85 (2002) 227-235
21. de Haan A., Geerligs H.J., Huchshorn J.P., van Scharrenburg G.J.M., Palache A.M., and Wilschut J. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13 (1995) 155-162
22. De Jonge M.I., Hamstra H.J., Jiskoot W., Roholl P., Williams N.A., Dankert J., Alphen Lv L.v., and Van Der Ley P. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 22 (2004) 4021-4028
23. Sakaue G., Hiroi T., Nakagawa Y., Someya K., Iwatani K., Sawa Y., Takahashi H., Honda M., Kunisawa J., and Kiyono H. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. 170 (2003) 495-502
24. de Haan A., Tomee J.F.C., Huchshorn J.P., and Wilschut J. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 13 (1995) 1320-1324
25. Stuart B.O. Deposition and clearance of inhaled particles. Environ. Health Perspect. 55 (1984) 369-390
26. Payne J.M., Sansom B.F., Garner R.J., Thomson A.R., and Miles B.J. Uptake of small resin particles (1-5 micron diameter) by the alimetary canal of the calf. Nature 188 (1960) 586-587
27. Jaafari M.R., Tafaghodi M., and Sajadi Tabasi S.A. Evaluation of the clearance characteristics of liposomes in the human nose by gamma-scintigraphy. Iranian J. Pharm. Res. 4 (2005) 25-35